In situ assay of acid sphingomyelinase and ceramidase based on LDL-mediated lysosomal targeting of ceramide-labeled sphingomyelin

Journal of Lipid Research

Volumn 37, Issue 12, 1996, Pages 2525-2538

  Levade, Thierry ^a   Leruth, Michèle ^b   Graber, Denis ^a   Moisand, André ^c   Vermeersch, Stéphane ^a   Salvayre, Robert ^a   Courtoy, Pierre J ^b  

^a INSERM   (France)

^b International Institute of Cellular and Molecular Pathology   (Belgium)

^c Lab Pharmacologie/Toxicologie F   (France)

Author keywords

Farber disease; I cell disease; Niemann Pick disease

Indexed keywords

ACYLSPHINGOSINE DEACYLASE; CERAMIDE; LOW DENSITY LIPOPROTEIN; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE;

ARTICLE; CELL LYSATE; CELL ULTRASTRUCTURE; ENZYME DEFICIENCY; EPSTEIN BARR VIRUS; FARBER DISEASE; GENE TARGETING; HUMAN; HUMAN CELL; INTERNALIZATION; LYSOSOME MEMBRANE; NIEMANN PICK DISEASE; PRIORITY JOURNAL; SKIN FIBROBLAST; VIRUS TRANSFORMATION;

AMIDOHYDROLASES; AUTORADIOGRAPHY; BIOLOGICAL ASSAY; CELL LINE; CERAMIDES; HUMANS; LIPOPROTEINS, LDL; LYSOSOMES; MICROSCOPY, ELECTRON; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELINS; TRITIUM;

EID: 0030481718     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Hannun, Y. A., and R. M. Bell. 1989. Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science. 243: 500-507.
2. Hakomori, S. 1990. Bifunctional role of glycosphingolipids. J. Biol. Chem. 265: 18713-18716.
3. Kolesnick, R. N. 1991. Sphingomyelin and derivatives as cellular signals. Prog. Lipid Res. 30: 1-38.
4. Koval, M., and R. E. Pagano. 1991. Intracellular transport and metabolism of sphingomyelin. Biochim. Biophys. Acta. 1082: 113-125.
5. Merrill, A. H. Jr., 1991. Cell regulation by sphingosine and more complex sphingolipids. J. Bioenerg. Biomembr. 23: 83-104.
6. M1 and sphingolipid breakdown products in cellular proliferation and signal transduclion pathways. Glyconjugate J. 9: 109-117.
7. Tager, J. M. 1985. Biosynthesis and deficiency of lysosomal enzymes. Trends Biochem. Sci. 10: 324-326.
8. Neufeld, E. F. 1991. Lysosomal storage diseases. Annu. Rev. Biochem. 60: 257-280.
9. O'Brien, J. S., and Y. Kishimoto. 1991. Saposin proteins: structure, function, and role in human lysosomal storage disorders. FASEB J. 5: 301-308.
10. Fürst, W., and K. Sandhoff. 1992. Activator proteins and topology of lysosomal sphingolipid catabolism. Biochim. Biophys. Acta. 1126: 1-16.
11. Gieselmann, V. 1995. Lysosomal storage diseases. Biochim. Biophys. Acta. 1270: 103-136.
12. Wenger, D. A., and C. Williams. 1991. Screening for lysosomal disorders. In Techniques in Diagnostic Human Biochemical Genetics. F .A. Hommes, editor. Wiley-Liss, New York, NY. 587-617.
13. Hannun, Y. A. 1994. The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem. 269: 3125-3128.
14. Neitzel, H. 1986. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum. Genet. 73: 320-326.
15. Levade, T., S. Gatt, A. Maret, and R. Salvayre. 1991. Different pathways of uptake and degradation of sphingomyelin by lymphoblastoid cells and the potential participation of the neutral sphingomyelinase. J. Biol. Chem. 266: 13519-13529.
16. Antonarakis, S. E., D. Valle, H. W. Moser, A. Moser, S. J. Qualman, and W. H. Zinkham. 1984. Phenotypic variability in siblings with Farber disease. J. Pediatr. 104: 406-409.
17. Levade, T., S. Gatt, and R. Salvayre. 1991. Uptake and degradation of several pyrenesphingomyelins by skin fibroblasts from control subjects and patients with Niemann-Pick disease. Biochem. J. 275: 211-217.
18. Poumay, Y., and M. F. Ronveaux-Dupal. 1985. Rapid preparative isolation of concentrated low density lipoproteins and of lipoprotein-deficient serum using vertical rotor gradient ultracentrifugation. J. Lipid Res. 26: 1476-1480.
19. Smith, P. K., R. I. Krohn, G. T. Hermanson, A. K. Mallia, F.H. Gartner, M.D. Provenzano, E.K. Fujimoto, N.M. Goeko, B.J. Olson, and D.C. Klenk. 1985. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150: 76-85.
20. Folch, J., M. Lees, and G. H. Sloane Stanley. 1957. A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226: 497-509.
21. Balch, W. E., and J. E. Rothman. 1985. Characterization of protein transport between successive compartments of the Golgi apparatus: asymmetric properties of donor and acceptor activities in a cell-free system. Arch. Biochem. Biophys. 240: 413-425.
22. Bradford, M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
23. Okada, S., and J. S. O'Brien. 1969. Tay-Sachs disease: generalized absence of β-D-N-acetylhexosaminidase component. Science. 165: 698-700.
24. Avruch, J., and D. F. H. Wallach. 1971. Preparation and properties of plasma membrane and endoplasmic reticulum fragments from isolated rat fat cells. Biochim. Biophys. Acta. 233: 334-347.
25. Pennington, R. J. 1961. Biochemistry of dystrophic muscle. Mitochondrial succinate-tetrazolium reductase and adenosine triphosphatase. Biochem. J. 80: 649-654.
26. Miller, A. L., V. Norton, R. Robertson, M. Jenks, R. Y. Yeh, and D. Wright. 1993. Light and heavy lysosomes: characterization of N-acetyl-β-D-hexosaminidase isolated from normal and I-cell disease lymphoblasts. Glycobiology. 3: 313-318.
27. Levade T., and S. Gatt. 1987. Uptake and intracellular degradation of fluorescent sphingomyelin by fibroblasts from normal individuals and a patient with Niemann-Pick disease. Biochim. Biophys. Acta. 918: 250-259.
28. Levade, T., M. C. Tempesta, and R. Salvayre. 1993. The in situ degradation of ceramide, a potential lipid mediator is not completely impaired in Farber disease. FEBS Lett. 329: 306-312.
29. Graber, D., R. Salvayre, and T. Levade. 1994. Accurate differentiation of nonneuropathic and nonneuropathic forms of Niemann-Pick disease by evaluation of the effective residual lysosomal sphingomyelinase activity in intact cells. J. Neurochem. 63: 1060-1068.
30. Levade T., R. Salvayre, J. C. Bes, M. Nezri and L. Douste-Blazy. 1985. New tools for the study of Niemann-Pick disease: analogues of natural substrate and Epstein-Barr virus-transformed lymphoid cell lines. Pediatr. Res. 19: 153-157.
31. Porter, M. T., A. L. Fluharty, J. Trammell, and H. Kihara. 1971. A correlation of intracellular cerebroside sulfatase activity in fibroblasts with latency in metachromatic leukodystrophy. Biochem. Biophys. Res. Commun. 44: 660-666.
32. Kudoh, T., and D. A. Wenger. 1982. Diagnosis of metachromatic leukodystrophy, Krabbe disease and Farber disease after uptake of fatty acid labeled cerebroside sulfate into cultured skin fibroblasts. J. Clin. Invest. 70: 89-97.
33. Bach, G., A. Dagan, B. Herz, and S. Gatt. 1987. Diagnosis of arylsulfatase A deficiency in intact cultured cells using a fluorescent derivative of cerebroside sulfate. Clin. Genet. 31: 211-217.
34. Inui, K., M. Furukawa, S. Okada, and H. Yabuuchi. 1988. Metabolism of cerebroside sulfate and subcellular distribution of its metabolites in cultured skin fibroblasts from controls, metachromatic leukodystrophy, and globoid cell leukodystrophy. J. Clin. Invest. 81: 310-317.
35. Leinekugel, P., S. Michel, K. Conzelmann, and K. Sandhoff. 1992. Quantitative correlation between the residual activity of β-hexosaminidase A and arylsulfatase A and the seventy of the resulting lysosomal storage disease. Hum. Genet. 88: 513-523.
36. Beaudet, A. L., and A. Manschreck. 1982. Metabolism of sphingomyelin by intact cultured fibroblasts: differentiation of Niemann-Pick disease types A and B. Biochem. Biophys. Res. Commun. 105: 14-19.
37. Kudoh, T., M. A. Velkoff, and D. A. Wenger. 1983. Uptake and metabolism of radioactively labeled sphingomyelin in cultured skin fibroblasts from controls and patients with Niemann-Pick disease and other lysosomal storage diseases. Biochim. Biophys. Acta. 754: 82-92.
38. Spence, M. W., J. T. R. Clarke, and H. W. Cook. 1983. Pathways of sphingomyelin metabolism in cultured fibroblasts from normal and sphingomyelin lipidosis subjects. J. Biol. Chem. 258: 8595-8600.
39. Vanier, M. T., R. Rousson, I. Garcia, G. Bailloud, M. C. Juge, A. Revol, and P. Louisot. 1985. Biochemical studies in Niemann-Pick disease. III. In vitro and in vivo assays of sphingomyelin degradation in cultured skin fibroblasts and amniotic fluid cells for the diagnosis of the various forms of the disease. Clin. Genet. 27: 20-32.
40. Koval, M., and R. E. Pagano. 1990. Sorting of an internalized plasma membrane lipid between recycling and degradative pathways in normal and Niemann-Pick, type A fibroblasts. J. Cell Biol. 111: 429-442.
41. Agmon, V., T. Dinur, S. Cherbu, A. Dagan, and S. Gatt. 1991. Administration of pyrene lipids by receptor-mediated endocytosis and their degradation in skin fibroblasts. Exp. Cell Res. 196: 151-157.
42. M2 gangliosidosis subjects. Eur. J. Biochem. 149: 247-255.
43. M1 ganglioside in cultured fibroblasts from normal individuals and patients with β-galactosidase deficiency. Biochim. Biophys. Acta. 875: 115-121.
44. M1 metabolism in living human fibroblasts with β-galactosidase deficiency. Hum. Genet. 73: 35-38.
45. M1 ganglioside in cultured skin fibroblasts: anomalies in gangliosidoses, sialidoses, and sphingolipid activator protein (SAP, saposin) 1 and prosaposin deficient disorders. Hum. Genet. 89: 513-518.
46. Saito, M., and A. Rosenberg. 1985. The fate of glucosylceramide (glucocerebroside) in genetically impaired (lysosomal β-glucosidase deficient) Gaucher disease diploid human fibroblasts. J. Biol. Chem. 260: 2295-2300.
47. Bieberich, E., and G. Legler. 1989. Intracellular activity of lysosomal glucosylceramidase measured with 4-nonylumbelliferyl β-glucoside. Biol. Chem. Hoppe-Seyler. 370: 809-817.
48. Kohen, E., C. Kohen, J. G. Hirschberg, R. Santus, G. Grabowski, W. Mangel, S. Gatt, and J. Prince. 1993. An in situ study of beta-glucosidase activity in normal and Gaucher fibroblasts with fluorogenic probes. Cell. Biochem. Funct. 11: 167-177.
49. 11C]hexanoyl)-D-erythro-glucosylsphingosine demonstrates a correlation between levels of residual enzyme activity and the type of Gaucher disease. Biochem. J. 303: 377-382.
50. Tanaka, H., and K. Suzuki. 1978. Globoid cell leukodystrophy (Krabbe's disease). Metabolic studies with cultured fibroblasts. J. Neurol. Sci. 38: 409-419.
51. M1-gangliosidosis. Biochim. Biophys. Acta. 835: 456-464.
52. Chen, W. W., and G. L. Decker. 1982. Abnormalities of lysosomes in human diploid fibroblasts from patients with Farber's disease. Biochim. Biophys. Acta. 718: 185-192.
53. Agmon, V., S. Cherbu, A. Dagan, M. Grace, G. A. Grabowski, and S. Gatt. 1993. Synthesis and use of novel fluorescent glycosphingolipids for estimating β-glucosidase activity in vitro in the absence of detergents and subtyping Gaucher disease variants following administration into intact cells. Biochim. Biophys. Acta. 1170: 72-79.
54. Kaneski, C. R., S. A. French, M. R. Brescia, M. J. Harbour, and S. P. F. Miller. 1994. Hydrolysis of a novel lysosomotropic enzyme substrate for β-galactosidase within intact cells. J. Lipid Res. 35: 1441-1451.
55. Lacorazza, H. D., and M. Jendoubi. 1995. In situ assessment of β-hexosaminidase activity. BioTechniques. 19: 434-439.
56. Rousseau, A., and S. Gatt. 1990. Uptake and degradation of virus-associated fluorescent sulfatide by skin fibroblasts. FEBS Lett. 261: 271-273.
57. Das, P. K., G. J. Murray, A. E. Gal, and J. A. Barranger. 1987. Glucocerebrosidase deficiency and lysosomal storage of glucocerebroside induced in cultured macrophages. Exp. Cell Res. 168: 463-474.
58. Van Weely, S., M. Brandsma, A. Strijland, J. M. Tager, and J. M. F. G. Aerts. 1993. Demonstration of the existence of a second, non-lysosomal glucocerebrosidase that is not deficient in Gaucher disease. Biochim. Biophys. Acta. 1181: 55-62.
59. Tempesta, M. C., R. Salvayre, and T. Levade. 1994. Functional compartments of sulphatide metabolism in cultured living cells: evidence for the involvement of a novel sulphatide-degrading pathway. Biochem. J. 297: 479-489.
60. Levade, T., F. Vidal, S. Vermeersch, N. Andrieu, S. Gatt, and R. Salvayre. 1995. Degradation of fluorescent and radiolabelled sphingomyelins in intact cells by a non-lysosomal pathway. Biochim. Biophys. Acta. 1258: 277-287.
61. Goldstein, J. L., and M. S. Brown. 1977. The low-density lipoprotein pathway and its relation to atherosclerosis. Annu. Rev. Biochem. 46: 897-930.
62. Levade T., H. W. Moser, A. H. Fensom, K. Harzer, A. B. Moser, and R. Salvayre. 1995. Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells. J. Neurol. Sci. 134: 108-114.
63. Levade T., H. Enders, M. Schliephacke, and K. Harzer. 1995. A family with combined Farber and Sandhoff, isolated Sandhoff and isolated fetal Farber disease: postnatal exclusion and prenatal diagnosis of Farber disease using lipid loading tests on intact cultured cells. Eur. J. Pediatr. 154: 643-648.
64. Klein A., M. Henseler, C. Klein, K. Suzuki, K. Harzer, and K. Sandhoff. 1994. Sphingolipid activator protein D (sap-D) stimulates the lysosomal degradation of ceramide in vivo. Biochem. Biophys. Res. Commun. 200: 1440-1448
65. Leighton F., B. Poole, H. Beaufay, P. Baudhuin, J. W. Coffey, S. Fowler and C. de Duve. 1968. The large-scale separation of peroxisomes, mitochondria and lysosomes from the livers of rats injected with Triton WR-1339. Improved isolation procedures, automated analysis, biochemical and morphological properties of fractions. J. Cell Biol. 37: 482-513.